U.S. market Closed. Opens in 1 day 3 hours 11 minutes

PLX | Protalix BioTherapeutics, Inc. Stock Fundamentals

(Stock Exchange: AMEX)
Analyzing fundamentals for PLX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is good and Health is frighteningly weak.

Valuation (24%)

Company Industry
P/E Ratio (TTM) -13.09 -15.27
PEG Ratio (TTM) -0.37 -4.35
P/S Ratio (TTM) 2.76 45.97
P/B Ratio (TTM) 3.88 28.96
P/FCF Ratio (TTM) 17.56 -2.59
Price to 5YR AVG Earnings Ratio -2.64 -5.56
Price to 5YR AVG FCF Ratio -7.27 -12.33

Profitability (0%)

Company Industry
ROA (TTM) -15.60% -19.06%
ROE (TTM) -30.89% 15.70%
Net Profit Margin (TTM) -21.04% -813.88%
ROIC 5YR AVG -143.01% 3.12%

Growth (68%)

4QTR AVG 3YR AVG 5YR AVG
EPS 24.73% 7.29% 44.07%
Revenue 57.47% 11.90% 19.48%
Net Income 24.14% -28.05% 25.52%
Cash Flow 49.05% -41.43% -34.53%

Health (21%)

Company Industry
Current Ratio (TTM) 1.98 5.56
Quick Ratio (TTM) 1.27 5.34
D/E Ratio (TTM) N/A 0.95
Interest Coverage (TTM) -4.77 -6.44
Piotroski F-Score 5 5
Altman Z-Score N/A 12.45
LTL to 5YR AVG FCF -0.27 0.11
Shares Outstanding Growth 5YR AVG 39.56% 37.46%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙